These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 36164414)

  • 21. Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study.
    Sheppard JD; Torkildsen GL; Lonsdale JD; D'Ambrosio FA; McLaurin EB; Eiferman RA; Kennedy KS; Semba CP;
    Ophthalmology; 2014 Feb; 121(2):475-83. PubMed ID: 24289915
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and Safety of OC-01 (Varenicline Solution) Nasal Spray on Signs and Symptoms of Dry Eye Disease: The ONSET-2 Phase 3 Randomized Trial.
    Wirta D; Vollmer P; Paauw J; Chiu KH; Henry E; Striffler K; Nau J;
    Ophthalmology; 2022 Apr; 129(4):379-387. PubMed ID: 34767866
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group.
    Stevenson D; Tauber J; Reis BL
    Ophthalmology; 2000 May; 107(5):967-74. PubMed ID: 10811092
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of Lifitegrast Ophthalmic Solution, 5.0%, in Patients With Moderate to Severe Dry Eye Disease: A Post Hoc Analysis of 2 Randomized Clinical Trials.
    Holland EJ; Jackson MA; Donnenfeld E; Piccolo R; Cohen A; Barabino S; Rolando M; Figueiredo FC
    JAMA Ophthalmol; 2021 Nov; 139(11):1200-1208. PubMed ID: 34617974
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years.
    Barber LD; Pflugfelder SC; Tauber J; Foulks GN
    Ophthalmology; 2005 Oct; 112(10):1790-4. PubMed ID: 16102833
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Masked Trial of a Topical Estradiol Ophthalmic Formulation in Postmenopausal Women with Moderate-to-Severe Dry Eye Disease.
    Schmidl D; Szalai L; Kiss OG; Schmetterer L; Garhöfer G
    Adv Ther; 2021 Apr; 38(4):1975-1986. PubMed ID: 33710587
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of 0.05% micellar nano-particulate (MNP) cyclosporine ophthalmic emulsion in the treatment of moderate-to-severe keratoconjunctivitis sicca: a 12-week, multicenter, randomized, active-controlled trial.
    Rao AT; Gupta A; Chauhan T; Basu S; Batra N; Sharma N; Sangwan VS; Gupta V; Mukherjee S
    BMC Ophthalmol; 2023 Mar; 23(1):121. PubMed ID: 36973703
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of cyclosporine 0.05% ophthalmic emulsion for contact lens-intolerant patients.
    Hom MM
    Eye Contact Lens; 2006 Mar; 32(2):109-11. PubMed ID: 16538135
    [TBL] [Abstract][Full Text] [Related]  

  • 29. NOV03 for Dry Eye Disease Associated with Meibomian Gland Dysfunction: Results of the Randomized Phase 3 GOBI Study.
    Tauber J; Berdy GJ; Wirta DL; Krösser S; Vittitow JL;
    Ophthalmology; 2023 May; 130(5):516-524. PubMed ID: 36574848
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Topical interleukin 1 receptor antagonist for treatment of dry eye disease: a randomized clinical trial.
    Amparo F; Dastjerdi MH; Okanobo A; Ferrari G; Smaga L; Hamrah P; Jurkunas U; Schaumberg DA; Dana R
    JAMA Ophthalmol; 2013 Jun; 131(6):715-723. PubMed ID: 23599118
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase 2 randomized, double-masked, placebo-controlled study of a novel integrin antagonist (SAR 1118) for the treatment of dry eye.
    Semba CP; Torkildsen GL; Lonsdale JD; McLaurin EB; Geffin JA; Mundorf TK; Kennedy KS; Ousler GW
    Am J Ophthalmol; 2012 Jun; 153(6):1050-60.e1. PubMed ID: 22330307
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Topical cyclosporine A therapy for dry eye syndrome.
    de Paiva CS; Pflugfelder SC; Ng SM; Akpek EK
    Cochrane Database Syst Rev; 2019 Sep; 9(9):CD010051. PubMed ID: 31517988
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An evaluation of the efficacy of a cyclosporine-based dry eye therapy when used with marketed artificial tears as supportive therapy in dry eye.
    Sall KN; Cohen SM; Christensen MT; Stein JM
    Eye Contact Lens; 2006 Jan; 32(1):21-6. PubMed ID: 16415689
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early Onset and Broad Activity of Reproxalap in a Randomized, Double-Masked, Vehicle-Controlled Phase 2b Trial in Dry Eye Disease.
    Clark D; Tauber J; Sheppard J; Brady TC
    Am J Ophthalmol; 2021 Jun; 226():22-31. PubMed ID: 33529588
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of 0.05% cyclosporine and 3% diquafosol solution for dry eye patients: a randomized, blinded, multicenter clinical trial.
    Park CH; Lee HK; Kim MK; Kim EC; Kim JY; Kim TI; Kim HK; Song JS; Yoon KC; Lee DH; Chung TY; Choi CY; Kim HS
    BMC Ophthalmol; 2019 Jun; 19(1):131. PubMed ID: 31208393
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Multicenter, Randomized, Double-Blind Evaluation of the Efficacy of TJO-087 Versus 0.05% Cyclosporine A in Moderate to Severe Dry Eye.
    Eom Y; Yoon KC; Kim HK; Song JS; Hyon JY; Kim HM
    J Ocul Pharmacol Ther; 2023; 39(1):27-35. PubMed ID: 36450107
    [No Abstract]   [Full Text] [Related]  

  • 37. A randomized controlled trial involving college student: Comparing 0.15% hyaluronic acid with 0.05% cyclosporine A and 3% diquafosol sodium in the Treatment of Dry Eye.
    Xu W; Zhao X; Jin H; Jin H; Jia F; Jiang L; Li Z
    Medicine (Baltimore); 2023 Sep; 102(36):e34923. PubMed ID: 37682142
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of 0.3% carbomer gel compared to placebo in patients with moderate-to-severe dry eye syndrome.
    Sullivan LJ; McCurrach F; Lee S; Taylor HR; Rolando M; Marechal-Courtois C; Creuzot-Garcher C; Easty DL; Karabatsas C; Bingh Hoh M; Faschinger C; Laroche L
    Ophthalmology; 1997 Sep; 104(9):1402-8. PubMed ID: 9307633
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety of Lifitegrast Ophthalmic Solution 5.0% in Patients With Dry Eye Disease: A 1-Year, Multicenter, Randomized, Placebo-Controlled Study.
    Donnenfeld ED; Karpecki PM; Majmudar PA; Nichols KK; Raychaudhuri A; Roy M; Semba CP
    Cornea; 2016 Jun; 35(6):741-8. PubMed ID: 27055211
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Randomized Multicenter Study Comparing 0.1%, 0.15%, and 0.3% Sodium Hyaluronate with 0.05% Cyclosporine in the Treatment of Dry Eye.
    Park Y; Song JS; Choi CY; Yoon KC; Lee HK; Kim HS
    J Ocul Pharmacol Ther; 2017 Mar; 33(2):66-72. PubMed ID: 27929721
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.